中美贸易摩擦对我国医药行业的影响及应对策略【摘要】文章以中国和美国近年来的贸易摩擦为背景，从我国医药对外发展现状入手，分析中美贸易摩擦对我国医药行业产生国际化发展面临重大挑战、加剧行业产能过剩、国际认证监管更严格、产业转型升级受阻等影响，从而延伸出我国进入国际医药市场存在受限于市场准入规则、科研技术能力不足、缺乏国际人才等问题，并针对这些问题给出中国医药企业国际化发展的合理建议，中国医药企业要通过加强药品质量管理，提高国际认证水平、实施国际化风险管理、开拓药品市场、实施同盟战略 重组医药企业和建设国际化人才队伍等方面提升自身国际竞争力。【关键词】中美贸易摩擦；医药行业；国际化发展The impact of trade friction between China and the United States on China's pharmaceutical industry and its countermeasures[Abstract]Based on the recent trade frictions between China and the United States, the article starts with the current development of China's pharmaceutical industry and analyzes the major challenges in the internationalization of China's pharmaceutical industry caused by the trade friction between China and the United States. The impact of transformation and upgrading is hindered, which extends the problems that China's access to the international pharmaceutical market is limited by market access rules, insufficient scientific research and technical capabilities, and lack of international talents. Based on these issues, it gives reasonable suggestions for the international development of Chinese pharmaceutical companies. Chinese pharmaceutical companies need to improve their international competitiveness by strengthening drug quality management, improving international certification levels, implementing international risk management, developing drug markets, implementing alliance strategies to restructure pharmaceutical companies, and building international talent teams.[Keywords]Trade frictions between China and...
